λ-Carrageenan Oligosaccharides of Distinct Anti-Heparanase and Anticoagulant Activities Inhibit MDA-MB-231 Breast Cancer Cell Migration.


Journal

Marine drugs
ISSN: 1660-3397
Titre abrégé: Mar Drugs
Pays: Switzerland
ID NLM: 101213729

Informations de publication

Date de publication:
27 Feb 2019
Historique:
received: 08 01 2019
revised: 15 02 2019
accepted: 22 02 2019
entrez: 2 3 2019
pubmed: 2 3 2019
medline: 18 6 2019
Statut: epublish

Résumé

In tumor development, the degradation of heparan sulfate (HS) by heparanase (HPSE) is associated with cell-surface and extracellular matrix remodeling as well as the release of HS-bound signaling molecules, allowing cancer cell migration, invasion and angiogenesis. Because of their structural similarity with HS, sulfated polysaccharides are considered a promising source of molecules to control these activities. In this study, we used a depolymerisation method for producing λ-carrageenan oligosaccharides (λ-CO), with progressive desulfation over time. These were then used to investigate the influence of polymeric chain length and degree of sulfation (DS) on their anti-HPSE activity. The effects of these two features on λ-CO anticoagulant properties were also investigated to eliminate a potential limitation on the use of a candidate λ-CO as a chemotherapeutic agent. HPSE inhibition was mainly related to the DS of λ-CO, however this correlation was not complete. On the other hand, both chain length and DS modulated λ-CO activity for factor Xa and thrombin IIa inhibition, two enzymes that are involved in the coagulation cascade, and different mechanisms of inhibition were observed. A λ-carrageenan oligosaccharide of 5.9 KDa was identified as a suitable anticancer candidate because it displayed one of the lowest anticoagulant properties among the λ-CO produced, while showing a remarkable inhibitory effect on MDA-MB-231 breast cancer cell migration.

Identifiants

pubmed: 30818840
pii: md17030140
doi: 10.3390/md17030140
pmc: PMC6471403
pii:
doi:

Substances chimiques

Anticoagulants 0
Antineoplastic Agents 0
Oligosaccharides 0
Carrageenan 9000-07-1
Heparitin Sulfate 9050-30-0
heparanase EC 3.2.1.-
Glucuronidase EC 3.2.1.31

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ligue Contre le Cancer
ID : Comité CD17 Charentes Maritimes et CSIRGO
Organisme : AAP Région Nouvelle Aquitaine
ID : "Nanovect" project

Références

J Biol Chem. 2000 Sep 29;275(39):30009-18
pubmed: 10862617
Int J Biol Macromol. 2001 Jun 12;28(5):395-9
pubmed: 11325427
J Clin Invest. 2001 Aug;108(3):341-7
pubmed: 11489924
Environ Health Perspect. 2001 Oct;109(10):983-94
pubmed: 11675262
Guang Pu Xue Yu Guang Pu Fen Xi. 2003 Jun;23(3):600-2
pubmed: 12953553
J Biol Chem. 2004 May 14;279(20):20824-35
pubmed: 14996843
Pharmacol Res. 2004 Jul;50(1):47-53
pubmed: 15082028
Pharmacol Res. 2005 Feb;51(2):153-7
pubmed: 15629261
J Biol Chem. 2005 Apr 1;280(13):12103-13
pubmed: 15647251
Pharmacol Res. 2006 Feb;53(2):129-34
pubmed: 16310373
Curr Pharm Des. 2007;13(20):2057-73
pubmed: 17627539
J Agric Food Chem. 2007 Aug 22;55(17):6910-7
pubmed: 17661479
Br J Cancer. 2007 Sep 17;97(6):761-8
pubmed: 17726466
Int J Mol Med. 2009 Dec;24(6):801-6
pubmed: 19885621
Thromb Haemost. 2009 Nov;102(5):907-11
pubmed: 19888527
Curr Med Chem. 2010;17(23):2503-29
pubmed: 20491645
PLoS One. 2011;6(6):e21106
pubmed: 21698156
Mol Vis. 2012;18:1649-57
pubmed: 22773903
Exp Ther Med. 2011 Mar;2(2):363-367
pubmed: 22977511
Carbohydr Polym. 2013 Jan 16;91(2):483-91
pubmed: 23121936
J Biol Chem. 2013 Jan 4;288(1):223-33
pubmed: 23161548
J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6
pubmed: 23420197
Int J Mol Med. 2013 May;31(5):1234-42
pubmed: 23467544
J Biomed Mater Res A. 2014 May;102(5):1431-8
pubmed: 23765560
Anal Bioanal Chem. 2014 Jan;406(1):249-65
pubmed: 24253408
Carbohydr Polym. 2014 Jan 30;101:776-85
pubmed: 24299838
Curr Cancer Drug Targets. 2014;14(3):286-93
pubmed: 24568197
J Med Chem. 2014 Jun 12;57(11):4511-20
pubmed: 24786387
Thromb Res. 2014 May;133 Suppl 2:S90-4
pubmed: 24862152
Adv Food Nutr Res. 2014;72:113-124
pubmed: 25081080
Methods Mol Biol. 2015;1229:105-18
pubmed: 25325948
Int J Clin Exp Pathol. 2014 Aug 15;7(9):5609-21
pubmed: 25337202
Food Chem. 2015 Jul 1;178:311-8
pubmed: 25704717
BMC Med. 2015 Mar 05;13:45
pubmed: 25857315
Carbohydr Polym. 2015 Jul 10;125:76-84
pubmed: 25857962
Mar Drugs. 2015 May 15;13(5):2967-3028
pubmed: 25988519
Sci Rep. 2015 Jun 22;5:11062
pubmed: 26098663
Adv Drug Deliv Rev. 2016 Feb 1;97:237-49
pubmed: 26555370
Nat Struct Mol Biol. 2015 Dec;22(12):1016-22
pubmed: 26575439
Glycobiology. 2016 Jun;26(6):640-54
pubmed: 26762172
Hum Vaccin Immunother. 2016 Sep;12(9):2253-6
pubmed: 27054564
Future Med Chem. 2016 Apr;8(6):647-80
pubmed: 27057774
Eur J Med Chem. 2016 Oct 4;121:209-220
pubmed: 27240275
Nat Biotechnol. 2016 Jun 9;34(6):625-30
pubmed: 27281424
Glycoconj J. 2017 Jun;34(3):411-420
pubmed: 27744520
Iran J Cancer Prev. 2016 Jun 15;9(4):e3836
pubmed: 27761203
Molecules. 2016 Nov 23;21(11):
pubmed: 27886097
Int J Biol Macromol. 2017 Mar;96:282-301
pubmed: 27914965
Carbohydr Polym. 2017 Jun 15;166:156-165
pubmed: 28385219
Mar Drugs. 2017 May 09;15(5):null
pubmed: 28486399
Clin Cancer Res. 2017 Oct 15;23(20):6267-6278
pubmed: 28710312
Chem Commun (Camb). 2017 Aug 10;53(65):9163-9166
pubmed: 28766595
Cancer Treat Rev. 2018 Apr;65:22-32
pubmed: 29502037
Molecules. 2018 Oct 19;23(10):null
pubmed: 30347648
Int J Cancer. 1987 Oct 15;40(4):511-8
pubmed: 3666989
Cancer Chemother Pharmacol. 1995;36(4):325-34
pubmed: 7628052
N Engl J Med. 1995 May 18;332(20):1330-5
pubmed: 7715641
Biochem J. 1993 Jan 15;289 ( Pt 2):331-4
pubmed: 8424778
J Surg Res. 1999 Jan;81(1):42-7
pubmed: 9889056

Auteurs

Hugo Groult (H)

Equipe BCBS (Biotechnologies et Chimie des Bioressources pour la Santé), Université de La Rochelle, UMR CNRS 7266 LIENSs, 17000 La Rochelle, France. hugo.groult@univ-lr.fr.

Rémi Cousin (R)

Equipe BCBS (Biotechnologies et Chimie des Bioressources pour la Santé), Université de La Rochelle, UMR CNRS 7266 LIENSs, 17000 La Rochelle, France. remi.cousin1@univ-lr.fr.

Caroline Chot-Plassot (C)

Equipe BCBS (Biotechnologies et Chimie des Bioressources pour la Santé), Université de La Rochelle, UMR CNRS 7266 LIENSs, 17000 La Rochelle, France. caroline.chotplassot@etudiant.univ-lr.fr.

Maheva Maura (M)

Equipe BCBS (Biotechnologies et Chimie des Bioressources pour la Santé), Université de La Rochelle, UMR CNRS 7266 LIENSs, 17000 La Rochelle, France. maheva.maura1@univ-lr.fr.

Nicolas Bridiau (N)

Equipe BCBS (Biotechnologies et Chimie des Bioressources pour la Santé), Université de La Rochelle, UMR CNRS 7266 LIENSs, 17000 La Rochelle, France. nicolas.bridiau@univ-lr.fr.

Jean-Marie Piot (JM)

Equipe BCBS (Biotechnologies et Chimie des Bioressources pour la Santé), Université de La Rochelle, UMR CNRS 7266 LIENSs, 17000 La Rochelle, France. jean-marie.piot@univ-lr.fr.

Thierry Maugard (T)

Equipe BCBS (Biotechnologies et Chimie des Bioressources pour la Santé), Université de La Rochelle, UMR CNRS 7266 LIENSs, 17000 La Rochelle, France. thierry.maugard@univ-lr.fr.

Ingrid Fruitier-Arnaudin (I)

Equipe BCBS (Biotechnologies et Chimie des Bioressources pour la Santé), Université de La Rochelle, UMR CNRS 7266 LIENSs, 17000 La Rochelle, France. ingrid.fruitier@univ-lr.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH